Says company yet to file audited accounts, without which it can't proceed.
Firms could lose licence if products not launched within 6 months of approval.
Executives caused loss of Rs 11 cr, according to police SIT.
An interview with Ranbaxy CEO and MD Arun Sawhney on the changes in the past four years and how the company plans to address the US concerns.
Sinha, who likes to keep a low profile, has seen his career go from one prestigious posting to another, writes Gyan Varma
SFIO official refuses to reveal the nature of additional charges found during investigation.
Sharad Pawar says final draft will go to Cabinet before Tuesday.
Company refuses to comment, says 'matters internal to organisation'
Another cap for imported insulin; domestic manufacturers cry foul.
FinMin had objected and wanted existing cost-plus method retained.
CCI to examine competition part of deals, RBI prudential aspects.
Work to begin after that on corrective measures to meet US regulator's requirements.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
Sun Pharma could have to withdraw cancer drug as J&J re-enters after temporary eclipse
Now, the companies need to get National Pharmaceutical Pricing Authority's nod for changing medicine composition. If they flout norms, government will take penal action.
GoM had proposed a new pricing mechanism, but judges had said at an earlier hearing the current formula should stay.
Ranbaxy was scheduled to launch its drug on September 21, the day Diovan's patent expired.
The move is significant, as this may prompt investigating agencies to take a look at the fresh accounting statements to be filed by the company to RoC, before taking a final call.
It was in 2005, India changed its patent law and started granting patents in medicines.
Agency seeks details of the period when Sushilkumar Shinde headed the ministry
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances